000			nab a22 7a 4500
999			_c16580 _d16580
003			PC16580
005			20210811105029.0
008			210805b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92598 _aSerrano, Manuel _eInstituto de Investigación i+12
100			_92597 _aMartinez-Flores, Jose A. _eInstituto de Investigación i+12
100			_92010 _aCastro Panete, María José _eInmunología
100			_91504 _aGarcía Martín, Florencio _eNefrología
100			_9821 _aLora Pablos, David _eInstituto Investigación I+12
100			_92937 _aPérez Méndez, Dolores _eInmunología
100			_91487 _aGonzález Monte, Esther _eNefrología
100			_91510 _aPaz Artal, Estela _eInmunología
100			_9576 _aMorales Cerdán, José María _eNefrología
100			_9661 _aSerrano Hernández, Antonio _eInmunología
245	0	0	_aRenal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease. _h[artículo]
260			_bJournal of immunology research, _c2014
300			_a2014:641962.
500			_aFormato Vancouver: Serrano M, Martínez Flores JA, Castro MJ, García F, Lora D, Pérez D et al. Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease. J Immunol Res. 2014;2014:641962.
501			_aPMID: 24818167 PMC4003762
504			_aContiene 57 referencias
520			_aIgA anti-beta-2-glycoprotein I (aB2GPI) antibodies have been related to vascular pathology in the general population and mainly in hemodialyzed patients (prevalence 33%) in whom an elevated incidence of thrombosis and mortality is found. In this paper we have studied the presence of IgA aB2GPI antibodies at pretransplant and their evolution after transplantation with a cross-sectional-based follow-up study of a cohort of 288 endstage renal disease (ESRD) patients treated with kidney transplantation. Pretransplant IgA aB2GPI levels were elevated 31.7 ± 4.2 U/mL without differences in age or type of dialysis. Patients with different etiologies of ESRD showed higher levels of IgA aB2GPI than blood donors, except the groups of non-IgA glomerular disease and systemic erythematosus lupus, whose nonsignificant differences were observed. IgA aB2GPI antibodies dropped immediately after transplantation (10.7 ± 1.0 U/mL, P < 0.0001), coinciding with a high degree of immunosuppression, and remained significantly lower than that observed in pretransplant status. Prevalence of patients with elevated antibodies was also less in transplanted patients (8.9% versus 30.4%, P < 0.0001). Among, positivity for IgA aB2GPI was higher than in patients who had received their first transplant that those were retransplanted. This finding could have important clinical implications and can suggest new therapeutic strategies in patients with IgA aB2GPI antibodies.
710			_986 _aServicio de Nefrología
710			_9395 _aServicio de Inmunología
710			_9625 _aInstituto de Investigación imas12
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003762/ _yAcceso libre
942			_2ddc _cART _n0